DavidWheeler United KingdomUniversity College London

DavidWheeler
David C WheelerrDavid is Professor of Kidney Medicine at University College London and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust. He is a clinical scientist interested in chronic kidney disease (CKD). He has participated in the development and delivery of several large-scale clinical trials testing lipid lowering regimens (SHARP), calcimimetics (EVOLVE), intravenous iron (PIVOTAL), SGLT2 inhibitors (CREDENCE and DAPA-CKD) and HIF stabilisers (ASCEND) in patients with CKD. He was co-chief investigator for the DAPA-CKD study (with Hiddo Lambers Heerspink). David has been involved in the development of Clinical Practice Guidelines for several organisations, most recently for Kidney Disease: Improving Global Outcomes (KDIGO). He served as KDIGO co-chair between 2012 and 2019. Other recent roles include Chair of the International Society of Nephrology Advancing Clinical Trials (ISN-ACTs) committee. In the UK, he is National Institute of Health Research (NIHR) Specialty Lead for Renal Disorders.
Institution

Day 2 - Monday April 15, 2024

Time Session
12:45 p.m.
1:30 p.m.
SPOT-15
AndreaViecelli Spotlight Speaker AustraliaUniversity of Queensland
Augusto CesarSoares dos Santos Junior Spotlight Speaker BrazilHospital das Clinicas, UFMG; Fac Ciências Medicas
BrendanSmyth Spotlight Speaker brendan.smyth@sydney.edu.auAustralia
DavidWheeler Spotlight Speaker United KingdomUniversity College London
MegJardine Spotlight Chairperson AustraliaNHMRC Clinical Trials Centre, University of Sydney, Australia
Spotlight Stage 1 (exhibition hall)

Day 3 - Tuesday April 16, 2024

Time Session
9 a.m.
10 a.m.
LF1002
DebasishBanerjee Chairperson United KingdomSt George's University Hospital NHS Foundation Tr
MegJardine Chairperson AustraliaNHMRC Clinical Trials Centre, University of Sydney, Australia
  • Setting the Scene
    MegJardine Speaker AustraliaNHMRC Clinical Trials Centre, University of Sydney, Australia
  • DM and CKD: Which Treatment Should I Use for Different Populations?
    KatherineTuttle Speaker United StatesUniversity of Washington School of Medicine, Division of Nephrology
  • How to Design Studies on Answering Unanswered Questions
    VladoPerkovic Speaker AustraliaUniversity of New South Wales, Sydney, Australia
  • The Effect of SGLT2 Inhibitors in Patients with Chronic Kidney Disease, With or Without Type 2 Diabetes
    DavidWheeler Speaker United KingdomUniversity College London
  • Q and A
Hall C4